Cervarix + Dengvaxia

This drug entry refers to the co-administration regimen of two distinct vaccines: the bivalent human papillomavirus (HPV) vaccine, **Cervarix**, and the tetravalent dengue vaccine, **Dengvaxia** (CYD-TDV). Cervarix, developed by GSK, is a recombinant vaccine composed of L1 protein virus-like particles (VLPs) of HPV types 16 and 18, formulated with the AS04 adjuvant system to prevent cervical cancer and related precancerous lesions. Dengvaxia, developed by Sanofi Pasteur, is a live-attenuated tetravalent chimeric vaccine built on a yellow fever 17D virus backbone, expressing the pre-membrane and envelope proteins of dengue virus serotypes 1, 2, 3, and 4. This combination was evaluated in Phase 3 clinical trials (notably NCT02292238) to assess the safety and immunogenicity of concomitant or sequential administration in adolescent females, particularly in regions where both HPV and dengue are endemic.

Other names

Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, RecombinantCYD Dengue VaccineTetravalent Dengue Vaccine